An Open-label Study of CND261 in Seropositive Rheumatoid Arthritis
Trial Parameters
Brief Summary
The purpose of the study is to evaluate the safety and efficacy of CND261 in patients with seropositive rheumatoid arthritis.
Eligibility Criteria
Inclusion Criteria: 1. 18 to 75 years old 2. Diagnosis of adult-onset RA 3. Class I-III RA 4. Moderately to severely active RA 5. Inadequate treatment response as defined in the protocol 6. Stable use of any concomitant therapies Exclusion Criteria: 1. Inadequate clinical laboratory parameters at Screening 2. Active infection 3. Receipt of or inability to discontinue any excluded therapies 4. Receipt of live vaccine within 4 weeks 5. Presence of any concomitant autoimmune disease 6. Active or known history of catastrophic anti-phospholipid syndrome 7. APS or thrombotic event not adequately controlled by anticoagulation therapy 8. History of progressive multifocal leukoencephalopathy 9. Central nervous system disease 10. Presence of 1 or more significant concurrent medical conditions 11. Have a diagnosis or history of malignant disease within 5 years 12. Serious mental illness, alcohol or drug abuse, dementia, or any other condition that would impair ability to receive planned treatment